With only a passing involvement with SBIR, AllCells has been for several decades a leading global provider in procuring and customizing primary cell products to support a diversity of CGT applications. Maintaining best-in-class products and services with optimized protocols designed to ensure on-time delivery of research and clinical-grade products to pharmaceutical, biotechnology, medical device, healthcare, and academic institutions around the world and by consistently delivering high-viability, high-purity subtypes and guaranteeing an accurate cell count, AllCells has earned a reputation for high-quality cells with the ability to customize product to meet even the most unique requirements. In July 2022 it was announced that ALLCells would be acquired by Discovery Ife Sciences. Combining AllCells' industry expertise with Discovery's biospecimen and biomarker specialization serves to establish a ptentially important provider for critical starting materials and analytic services to accelerate CGT applications. a leading provider of high-quality human primary blood and marrow-based cells.
